ASNase has been a cornerstone of the treatment of leukaemia for decades, but given the results of our work, ASNS may also be a novel therapeutic target in non-malignant, autoimmune disease mediated by the GC reaction, and is deserving of future study in this context. This evidence concerns the gene ASNS and leukemia.